期刊文献+

OPG水平与冠心病合并慢性肾功能不全患者冠脉病变程度及近期预后的关系 被引量:1

Relationship between serum osteoprotegerin and coronary artery disease with renal insufficiency and short-term prognosis
原文传递
导出
摘要 目的探讨血清护骨素(OPG)水平与冠心病合并慢性肾功能不全患者冠脉病变程度及近期预后的关系。方法 202例慢性肾功能不全住院患者,根据冠脉造影结果分为冠脉正常或轻度粥样硬化组51例(D组),单支病变组52例(A组),双支病变组51例(B组),三支病变组48例(C组)。ELISA法检测血清OPG水平,并分析其与冠脉病变程度、高血压、糖尿病、肾功能不全之间的关系。对患者进行1年随访,记录主要终点事件:再发急性冠脉综合征、心源性死亡、病死率、缺血性中风、发展为尿毒症期或维持透析。结果血清OPG水平随冠脉病变支数增加而升高。D组、A组、B组和C组血清OPG水平分别为(205.42±86.18)ng/L、(284.98±183.30)ng/L、(322.56±161.95)ng/L和(430.95±211.92)ng/L(P<0.01)。随访(14.7±1.2)个月。14例(7.3%)患者达到终点事件,血清OPG水平为(428.96±197.13)ng/L,高于未发生事件者的(303.10±182.75)ng/L(P<0.05)。结论冠心病合并慢性肾功能不全患者,OPG水平越高,冠脉病变程度越严重,近期预后越差。 Objective To examine whether serum osteoprotegerin(OPG) levels are associated with the severity of coronary artery lesions and 1-year prognosis.Methods Serum OPG levels were examined by ELISA kit in 202 patients with chronic renal insufficiency who underwent coronary angiography.The number of diseased vessels was used to represent the severity of coronary artery disease(CAD).The patients were divided into four groups of D(normal coronary arteries and mild coronary atherosclerosis),A(1-vessel lesion),B(2-vessel lesion) and C(3-vessel lesion).The patients were followed up for average 14 months.The endpoints included recurrence of acute coronary syndrome,cardiac death,total mortality,ischemic stroke,uremia and dialysis.Results The serum OPG levels increased as CAD became severe,which were(205.42±86.18) ng/L in group D,(284.98±183.30) ng/L in group A,(322.56±161.95) ng/L in group B,and(430.95±211.92) ng/L in group C(P〈0.01).A total of 14(7.3%) cases occurred the endpoints with a higher OPG of(428.96±197.13) ng/L,which was higher than(303.10±182.75) ng/L in those did not(P〈0.05).Conclusion In CAD patients with chronic renal insufficiency,the higher OPG levels,the severer CAD disease and poorer the short-term prognosis.
出处 《江苏医药》 CAS CSCD 北大核心 2012年第2期181-183,共3页 Jiangsu Medical Journal
关键词 冠状动脉疾病 肾功能不全 护骨素 Coronary artery disease Renal insufficiency Osteoprotegerin
  • 相关文献

参考文献10

  • 1Vik A,Mathiesen EB,Brox J,et al.Serum osteoprotegerinis a predictor for incident cardiovascular disease and mortalityin a general population:the Troms Study[J].J ThrombHaemost,2011,9(4):638-644.
  • 2Mesquita1M,Demulder A,Damry N.Plasma osteoprotegerinis an independent risk factor for mortality and an early bio-marker of coronary vascular calcification in chronic kidneydisease[J].Clin Chem Lab Med,2009,47(3):339-346.
  • 3Simonet WS,Lacey DL,Dunstan CR,et al.Osteoprotegerin:anovel secreted protein involved in the regulation of bonedensity[J].Cell,1997,89(2):309-319.
  • 4Bolon B,Shalhoub V,Paul JK,et al.Osteoprotegerin,anendogenous antiosteoclast factor for protecting bone in rheu-matoid arthritis[J].Arthritis Rheumatism,2002,46(12):3121-3135.
  • 5Lieb W,Gona P,Larson M,et al.Biomarkers of the osteo-protegerin pathway:clinical correlates,subclinical disease,incident CVD and mortality[J].Arterioscler Thromb VascBiol,2010,30(9):1849-1854.
  • 6Reinhard H,Lajer M,Gall MA,et al.Osteoprotegerin andmortality in type 2diabetic patients[J].Diabetes care,2010,33(12):2561-2566.
  • 7Kazama J,Shigematsu T,Yano K,et al.Increased circulatingosteoclastogenesis inhibitory factor(osteoprotegerin)inpatients with chronic renal failure[J].Am J Kidney Dis,2002,39(3):525-532.
  • 8Sato T,Tominaga Y,Iwasaki Y,et al.Osteoprotegerin levelsbefore and after renal transplantation[J].Am J Kidney Dis,2001,38(Suppl1):S175-177.
  • 9Semb A,Ueland T,Aukrust P,et al.Osteoprotegerin andsoluble receptor activator of nuclear factor-kappab ligand andrisk for coronary events:a Nested case-control approach in theprospective EPIC-Norfolk population study 1993-2003[J].Arterioscler Thromb Vasc Biol,2009,29(6):975-980.
  • 10王小斌,单其俊,马根山,杨志健,朱铁兵,王连生,曹克将,马文珠.骨保护素与冠心病关系的探讨[J].中华心血管病杂志,2004,32(6):501-503. 被引量:6

二级参考文献10

  • 1Dhore CR,Cleutjens JP,Lutgens E,et al.Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques[].Arteriosclerosis Thrombosis and Vascular Biology.2001
  • 2Browner WS,Lui LY,Cummings SR.Association of serum osteoprotegerin levels with diabetes,stroke,bone density, fractures, and mortality in elderly women[].The Journal of Clinical Endocrinology.2001
  • 3Ross R: Atherosclerosis-An inflammatory disease. The New England Journal of Medicine . 1999
  • 4Simonet WS,Lacey DL,Dunstan CR,et al.Osteoprotegerin:anovel secreted protein involved in the regulation of bone density[].Cell.1997
  • 5Yano K,Tsuda E,Washida N,et al.Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis[].Journal of Bone and Mineral Research.1999
  • 6Yun TJ,Chaudhary PM,Shu GL,et al.OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is upregulated by ligating CD40[].J Immunol.1998
  • 7Hofbauer LC,Khosla S,Dunstan CR,et al.The role of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption[].Journal of Bone and Mineral Research.2000
  • 8Bucay N,Sarosi I,Dunstan CR,et al.Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification[].Genes and Development.1998
  • 9Min H,Morony S,Sarosi I,et al.Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis[].The Journal of Experimental Medicine.2000
  • 10Malyankar UM,Scatena M,Suchland KL,et al.Osteoprotegerin is an alpa vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells[].Journal of Biological Chemistry.2000

共引文献5

同被引文献21

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部